A different type of COVID-19 vaccine shows early promise
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Early clinical testing of a Chinese vaccine against COVID-19 has shown promise, with the vaccine able to trigger anitbody production and also showing a low rate of adverse reactions. The vaccine is based on an inactivated version of the whole SARS-CoV-2 virus - unlike some other vaccines in development, which only use a part of the SARS-CoV-2 virus.
Journal/conference: JAMA
Link to research (DOI): 10.1001/jama.2020.15543
Organisation/s: China National Biotec Group Company Limited
Funder: This study was supported by the
National Program on Key Research Project of China
(2020YFC0842100) and Major Science and
Technology Project of the National New Drug
Development of China (2018ZX09734-004).
The vaccine was developed and the study was
sponsored by the China National Biotec Group Co
Ltd and
Attachments:
Note: Not all attachments are visible to the general public
